New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
16:13 EDTACT, TKPYYActavis confirms patent challenge on generic Colcrys
Actavis (ACT) confirmed that it has filed an Abbreviated New Drug Application with the U.S. FDA seeking approval to market Colchicine Tablets USP, 0.6 mg. Actavis' ANDA product is a generic version of Takeda's (TKPYY) Colcrys, which is a prescription medicine used in adults to prevent and treat gout flares. Takeda Pharmaceuticals U.S.A. filed suit against Actavis on February 27 in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.
News For ACT;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 17, 2014
12:12 EDTACTActavis, Allergan deal 'great' for both companies, says BMO Capital
Subscribe for More Information
11:14 EDTACTActavis says 2017 EPS goal of $25 does not include 'transformational' M&A
Subscribe for More Information
09:39 EDTACTActavis CEO says 'aspirational goal' is to grow EPS to $25 by 2017
Subscribe for More Information
09:34 EDTACTCombined Actavis-Allergan to be led by Actavis CEO Saunders
Actavis (ACT) and Allergan (AGN) said The combined company will be led by Brent Saunders, CEO and President of Actavis, and Paul Bisaro will remain Executive Chairman of the Board. The integration of the two companies will be led by the senior management teams of both companies, with integration planning to begin immediately in order to transition rapidly to a single company. Additionally, two members of the Allergan board of directors will be invited to join the Actavis Board of Directors following the completion of the transaction.
09:32 EDTACTValeant says cannot justify paying $219 per share for Allergan
Valeant Pharmaceuticals (VRX) commented on the announcement that Allergan (AGN) and Actavis (ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock: "We have seen the announcement that Allergan and Actavis have made, and while we will review any such agreement in determining our course of action, Valeant cannot justify to its own shareholders paying a price of $219 or more per share for Allergan. Our business is performing extremely well as evidenced by our third quarter results, our expected strong fourth quarter, and our robust outlook for 2015, and I am confident in our continued ability to generate exceptional shareholder value. We will remain focused on delivering strong organic results and evaluating acquisition opportunities as we always have: prudently, in a disciplined manner, and in the best interests of our shareholders."
09:29 EDTACTActavis to host conference call
Conference call to discuss the acquisition of Allergan will be held on November 17 at 10:30 am. Webcast Link
09:24 EDTACTAllergan up over 5% to $209 after agreeing to be acquired by Actavis
Subscribe for More Information
09:22 EDTACTOn The Fly: Pre-market Movers
Subscribe for More Information
09:21 EDTACTActavis, Allergan transaction subject to approval of shareholders of both
Subscribe for More Information
09:20 EDTACTActavis projects at least $1.8B in annual synergies from Allergan transaction
Subscribe for More Information
09:18 EDTACTActavis sees free cash flow over $8B in 2016 following Allergan acquisition
Subscribe for More Information
09:16 EDTACTActavis confirms deal to acquire Allergan for $219 in cash, stock
Subscribe for More Information
09:15 EDTACTActavis confirms deal to acquire Allergan for $219 in cash and shares
Subscribe for More Information
09:10 EDTACTActavis buying Allergan for $219 per share, CNBC reports
08:02 EDTACTActavis completes Durata Therapeutics tender offer
Subscribe for More Information
06:05 EDTACTActavis close to buying Allergan for over $64B, Bloomberg reports
Subscribe for More Information
November 16, 2014
14:02 EDTACTAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information
November 14, 2014
16:58 EDTACTThird Point gives quarterly update on stakes
NEW STAKES: Alibaba (BABA), eBay (EBAY), Bed Bath & Beyond (BBBY), Shire (SHPG), and Parker Hannifin (PH). INCREASED STAKES: Actavis (ACT), Amgen (AMGN), EQT (EQT), Sensata (ST), Coca-Cola Enterprises (CCE). DECREASED STAKES: Williams Cos (WMB), Ally Financial (ALLY), Cheniere Energy (LNG), YPF (YPF), and FedEx (FDX). LIQUIDATED STAKES: AIG (AIG), T-Mobile (TMUS), Rackspace (RAX), Hertz (HTZ), and Citrix Systems (CTXS).
12:53 EDTACTOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
07:32 EDTACTHayman Capital gives quarterly update on stakes
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use